Background: The subcutaneous implantable cardioverter-defibrillator (S-ICD) is an effec-
| INTRODUCTION
The practice of defibrillation threshold testing (DFT) or of defibrillation verification at the time of transvenous implantable cardioverterdefibrillators (ICDs) implant has decreased along years, based on similar patients' outcome irrespectively of DFT testing. 1 Contemporary recommendations for defibrillation verification focus on selected populations and on atypical implant configurations. 2 The recently developed subcutaneous ICD (S-ICD) is an effective alternative to transvenous ICD that does not require an endovascular lead placement. 3, 4 However, studies on the safety of DFT avoidance are still lacking with S-ICD, as well as studies investigating the factors potentially associated with higher DFTs. For this reason, functional defibrillation testing is still recommended at S-ICD implantation. 2 Current S-ICD devices deliver a maximum of 80 J, thus the test is usually conducted by delivering a shock energy of 65 J to ensure a safety defibrillation margin of at least 15 J. Recent findings from clinical practice in the US and Europe [5] [6] [7] [8] show high rates (above 90%) of successful conversion at ≤65 J, but limited data on the conversion success at lower energies exist.
The aim of this study was to describe our experience of ventricular fibrillation (VF) termination with lower energy S-ICD shocks, and to identify factors potentially associated with test failure.
2 | METHODS
| Study design
We included in this analysis all consecutive patients undergoing implantation of an S-ICD (Boston Scientific Inc., Natick, Massachusetts) from February 2015 to October 2018 at our Institution. The
Institutional Review Board approved the study, and all patients provided written informed consent for data storage and analysis. Baseline assessment comprised the collection of demographic data and medical history, clinical examination, 12-lead electrocardiogram, echocardiographic evaluation, magnetic resonance scanning, and coronary angiography (when clinically indicated). An adequate S-ICD sensing was verified before implantation by the surface electrocardiogram (ECG) screening method that is based on a dedicated ECG morphology tool. As the confidence in the system increased, we lowered the first-attempt energy to understand the defibrillation efficacy in a real-life unselected population of S-ICD recipients. In case of failure, the second trial at defibrillation verification used a higher energy, in any case ≤60 J. In the event of a second failure at higher energy, reverse polarity at the secondly tested energy was used.
There was no systematic approach at the choice of the first attempt delivered energy based on specific patients' characteristics such as body mass index (BMI) or ejection fraction. 3 | RESULTS
| Statistical analysis

| Study population and S-ICD implantation procedure
A total of 72 patients underwent S-ICD implantation. Table 1 shows the baseline clinical variables in the study population. Patients were predominantly male (74%), relatively young (47 ± 17 years), and only a minority showed severely depressed systolic function (28% with left ventricular ejection fraction ≤35%). The S-ICD generator was positioned in a standard subcutaneous pocket in 30 (42%) patients, while an inter-muscular approach was adopted in the remaining patients ( Figure 1 ). In 49 (68%) patients, the S-ICD generator was located superiorly to the cardiac apical shadow on supine fluoroscopy.
| Efficacy of VF termination
In 8 (11%) patients, defibrillation verification was not performed for unwillingness of the parents (2 minors) or patient refusal (1 adult patient), clinical instability in 2 heart failure patients, and non-inducibility of sustained VF in three patients. Of the remaining 64 patients who underwent defibrillation verification, 38 had an intermuscular, and 26 a subcutaneous generator placement; the first conversion attempt occurred at a mean shock energy of 33 ± 7 J with a shock impedance of 77 ± 22
Ohm, respectively at 31 ± 7 J (impedance 75 ± 23 Ohm) in intermuscular implants and at 35 ± 5 J (impedance 82 ± 18 Ohm) in subcutaneous implants, and was successful in 50 patients (78%). A second test, performed at a mean energy of 47 ± 11 J, was successful in the 14 patients in which the first shock did not convert VF.
The first successful attempt was delivered at 31 ± 8 J in intermuscular device recipients, and at 36 ± 5 J in subcutaneous device recipients (P = .014). In particular, successful defibrillation was obtained On logistic regression analysis of clinical characteristics (Table 2) 
| DISCUSSION
In our experience of VF termination at the time of S-ICD implantation, we observed high defibrillation success rates at low energy, suggesting that the safety margin of currently adopted systems is frequently higher than the usually accepted 15 J. Moreover, we found that ejection fraction ≤35% was associated with test failure. Nonetheless, when low ejection fraction patients are considered, a first attempt at ≤40 J was effective in 90% of intermuscular S-ICD recipients compared with only 16% of subcutaneous recipients. : our study is indeed more powered to assess the role of hypertrophy, because 33% of our patients had hypertrophic cardiomyopathy (the six with wall thickness in the 30-41 mm range had successful VF termination with ≤30 J), and the mean wall thickness of the whole population was 16 ± 8 mm, well above other literature reports. [3] [4] [5] [6] [7] [8] 12, 13 As described by Friedman et al., 13 severely decreased ejection fraction was associated to a lower defibrillation safety margin also in our experience. However, defibrillation was successful at low shock energies even in patients with ejection fraction ≤35% in intermuscular implants, failure at ≤40 J being more common in the setting of a subcutaneous device placement.
Based on present results, larger studies are warranted to investigate whether lower defibrillation energies can reliably terminate VF in S-ICD indications recipients, once an optimized implant is achieved:
only two of the intermuscular recipients failed an attempt at ≤40 J in our series, though a well-designed study with a strict methodology is required to prove the consistency of our observations on consecutive, unselected S-ICD recipients. A 95% success rate at 45 J would enable to decrease the maximum S-ICD output at 60 J, thereby increasing its longevity to state-of-the-art transvenous ICDs, 14 or could promote manufacturing of smaller devices meeting the clinical needs of pediatric as well as of small body habit patients. 15 Indeed, although it has been recently shown that S-ICD implantation is safe and effective in children and young adults, 15 they would either benefit of a smaller can for acceptability or of long-lasting S-ICDs to avoid frequent replacements, that increase infection risk. 16 The demonstration that the safety margin of currently adopted S-ICD is frequently higher than what generally accepted for transvenous ICDs is also reassuring in situations where the defibrillation test is not performed.
This occurred in 11% of our patients and in 19% of previous larger samples, 8 for clinical reasons or for lack of VF inducibility. Most recent reports show that, despite a Class I recommendation, VF termination testing is declining in clinical practice due to physician preference. 13 Definite data will derive from the ongoing randomized Trial of S-ICD implantation with and without defibrillation testing (PRAETORIAN-DFT), which aims to prove the safety of withholding defibrillation verification when implant optimization is based on the PRAETORIAN score. 17 
| Limitations
This study is limited by its retrospective design, the small sample size, and the non-uniform defibrillation testing protocol. In particular, we did not apply a step-down or a small step-up/reverse polarity testing in case of first attempt failure to accurately calculate the DFT. Nonetheless, the first-attempt energy delivered was superior in subcutaneous S-ICD recipients, which confirms the advantage of an intermuscular placement.
| Conclusions
Our study shows a high rate of defibrillation success at low-energy shock in consecutive S-ICD recipients. Patients with reduced ejection fraction showed higher energy requirements, especially when placed subcutaneously. We believe that these observations are hypothesisgenerating for an accurate study to prove that a 60 J maximum output device may be as effective as an 80 J one, in a view to improve device longevity and/or suit small-habit/pediatric patients.
